Hemostasis Today

March, 2026
March 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Sarah Alrasheed: New Evidence on Transitioning From Parenteral Prostacyclin to Selexipag
Dec 10, 2025, 11:59

Sarah Alrasheed: New Evidence on Transitioning From Parenteral Prostacyclin to Selexipag

Sarah Alrasheed, Associate Consultant in Pulmonary Medicine at King Faisal Specialist Hospital and Research Center, shared on LinkedIn:

“I am pleased to share that our latest research has been published in Pulmonary Circulation. In this study, we address a critical and sensitive clinical question: the transition from parenteral prostacyclin therapy to Selexipag.

Until now, many of us in clinical practice have had limited evidence to guide whether transitioning to oral prostacyclin pathway therapy is safe and feasible, and most importantly: what the safety implications of this decision are for our patients. Our findings aim to provide practical, real world guidance to support clinicians facing this complex decision.

I hope this work proves valuable for your practice and for the care of patients with pulmonary hypertension.

You can access the article here.”

Article: Transitioning From Parenteral Prostanoids to Oral Selexipag in Pulmonary Arterial Hypertension: A Multicenter Retrospective Cohort Study

Authors: Brandon Budhram, Sarah K. Alrasheed, Moaaz Rashad, George Chandy, Anna Dvorkin-Gheva, George A. Fox, Julia Foxall, Andrea Gardner, Doug Helmersen, Naushad Hirani, Kristina Kemp, Mithum Kularatne, David Langleben, Lyda Lesenko, Steeve Provencher, Emma Spence, John R. Swiston, Mitesh Thakrar, Daniel Wadden, Jason Weatherald, Nathan Hambly

Sarah Alrasheed

Stay updated on all scientific advances with Hemostasis Today.